Applied Therapeutics, Inc. (APLT): Price and Financial Metrics


Applied Therapeutics, Inc. (APLT): $0.87

-0.08 (-8.77%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

APLT Stock Price Chart Interactive Chart >

Price chart for APLT

APLT Price/Volume Stats

Current price $0.87 52-week high $22.27
Prev. close $0.95 52-week low $0.73
Day low $0.86 Volume 401,100
Day high $0.94 Avg. volume 420,513
50-day MA $1.46 Dividend yield N/A
200-day MA $6.39 Market Cap 22.70M

Applied Therapeutics, Inc. (APLT) Company Bio


Applied Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company was founded by Shoshana Shendelman on January 20, 2016 and is headquartered in New York, NY


APLT Latest News Stream


Event/Time News Detail
Loading, please wait...

APLT Latest Social Stream


Loading social stream, please wait...

View Full APLT Social Stream

Latest APLT News From Around the Web

Below are the latest news stories about Applied Therapeutics Inc that investors may wish to consider to help them evaluate APLT as an investment opportunity.

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

Good morning, trader!

William White on InvestorPlace | January 4, 2022

Why Applied Therapeutics Stock Is Sliding Today

The company's lead candidate, AT-007, is going to take a lot longer to reach patients than expected.

Yahoo | January 3, 2022

Applied Therapeutics To Hold Filing FDA Application For AT-007 In Rare Metabolic Disorder

Following discussions with the FDA, Applied Therapeutics Inc (NASDAQ: APLT) has decided to hold on submitting a marketing application for AT-007 for Galactosemia pending additional talks with the agency. Although the Galactosemia program had previously been discussed for Accelerated Approval based on reduction in galactitol, the FDA has now indicated that clinical outcomes data will likely be required for approval. Related: Applied Therapeutics Stock Drops On Delayed NDA Submission For Its Lead

Yahoo | January 3, 2022

Applied Therapeutics Provides Regulatory Update on Galactosemia Program

NEW YORK, Jan. 03, 2022 (GLOBE NEWSWIRE) -- Applied Therapeutics, Inc. (Nasdaq: APLT), a clinical-stage biopharmaceutical company developing a pipeline of novel drug candidates against validated molecular targets in indications of high unmet medical need, today provided a regulatory update on the AT-007 Galactosemia program. Following discussions with the FDA at the end of the year, the Company has decided to hold on submitting an NDA for AT-007 for treatment of Galactosemia pending additional d

Yahoo | January 3, 2022

Applied Therapeutics Tanks as Drug Candidate for Rare Disease Faces Delays

By Dhirendra Tripathi

Yahoo | January 3, 2022

Read More 'APLT' Stories Here

APLT Price Returns

1-mo -29.27%
3-mo -65.06%
6-mo -85.05%
1-year -95.82%
3-year -89.47%
5-year N/A
YTD -90.28%
2021 -59.34%
2020 -19.32%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4523 seconds.